NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Health Information Services · USD

Tempus AI, Inc. (TEM) Stock Analysis

Tempus AI, Inc. (TEM) is a Health Information Services stock listed on NASDAQ and quoted in US Dollar.

TEM

$64.62

−$0.04 (−0.06%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare TEM with… →

TEM Key Statistics

As of Sep 4, 2026
Trading
Open
$64.76
Previous Close
$64.66
Day's Range
63.11–66.30
52-Week Range
40.77–104.32
Volume
4.57M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
3.72
Valuation
Market Cap
$11.66B
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
8.14
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.44
Financials (FY)
Revenue (FY)
$1.27B+83.41%
Net Income (FY)
−$245.03M
Profit marginThe share of revenue left as profit after all costs and taxes.
−17.77%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
175.39M
1-Year Return
−17.28%
Dividend and dates
Earnings Date
November 3, 2026estimated
Avg Volume
6.46M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

TEM Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+9.43%
2025+74.91%
2024 (partial year)−16.12%

As of September 4, 2026.

TEM Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$1.27B−$245.03M−19.3%
2024$693.40M−$705.81M−101.8%
2023$531.82M−$214.12M−40.3%
2022$320.67M−$289.81M−90.4%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$1.27B$797.90M−$252.87M−$245.03M−19.3%
2024$693.40M$381.11M−$691.08M−$705.81M−101.8%
2023$531.82M$286.18M−$196.08M−$214.12M−40.3%
2022$320.67M$130.19M−$265.44M−$289.81M−90.4%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

TEM Valuation vs Health Information Services Median

Median of 53 stocks
MetricTEMHealth Information Services medianvs median
P/S ratio8.142.663.1x the median
Profit margin−17.77%0.00%17.8 pts below

Medians across 53 Health Information Services stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Tempus AI, Inc. (TEM) is capitalised at $11.66B on the latest close. The company sits in the Healthcare sector, in the Health Information Services industry. Headcount on file is 3,800.

TEM last closed at $64.62 on September 4, 2026. That is −$0.04 (−0.06%) against the previous close. The 52-week range on file runs from $40.77 to $104.32. The latest close sits 58.5% above that 52-week low.

Financial Health

In fiscal 2025, Tempus AI, Inc. reported revenue of $1.27B. That is +83.41% against the prior fiscal year, when revenue was $693.40M. The same year closed with a net loss of $245.03M. The reported profit margin is −17.77%. That is 17.8 percentage points below the Health Information Services median of 0%. Earnings per share on a trailing basis come to −1.44.

Across the 4 fiscal years on file, revenue moves from $320.67M in 2022 to $1.27B in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. Measured against sales, the shares trade at 8.14 times revenue. On price-to-sales that is 3.1 times the Health Information Services median of 2.66. The medians here are taken across 53 Health Information Services companies that report the metric.

The reported beta is 3.72. Annualized volatility over the trailing 2 years is 93.74%. The trailing one-year price return is −17.28%. The stored price history starts on June 14, 2024, and the total return since then is +60.55%.

Growth & Income

The record shows no dividend for TEM.

The record holds one complete calendar year, 2025, which returned +74.91%. 2026 is still running; the price is +9.43% year to date.

Peer Comparison

Tempus AI, Inc. (TEM) operates in the Health Information Services industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Tempus AI, Inc. TEM $11.66B —
Veeva Systems Inc. VEEV $44.54B 45.0
BrightSpring Health Services, Inc. BTSG $12.02B 54.7
HealthEquity, Inc. HQY $7.95B 35.7

The Health Information Services industry average P/E ratio is 41.1x. Tempus AI, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Health Information Services Stocks

VEEV

Veeva Systems Inc.

$44.54B

 BTSG

BrightSpring Health Services, Inc.

$12.02B

 HQY

HealthEquity, Inc.

$7.95B

 HNGE

Hinge Health, Inc.

$7.45B

 WAY

Waystar Holding Corp.

$4.81B

 DOCS

Doximity, Inc.

$4.70B
View all Health Information Services stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Tempus AI, Inc.

Tempus AI, Inc. operates as a healthcare technology company in the United States. It offers the Tempus platform, a closed-loop, full-stack, bi-directional integrations between a clinician's desktop and its laboratory diagnostic capabilities, analytics platform, and repository of multimodal data; and Hub, a clinical application for physicians and other healthcare providers for use in the diagnostics product line as an end-to-end application for healthcare providers for NGS tests. The company also provides Lens, a software application for life sciences and advanced precision research; diagnostics services, such as NGS diagnostics, PCR profiling, and other anatomic and molecular pathology tests; and large-panel solid tumor and hematologic testing through multiple assays, with its core clinical assay (xT and xR) offering large panel DNA, RNA full transcriptome, and incidental germline findings through normal blood or saliva analyses. In addition, it provides genetic tests focused on inherited conditions; an nP assay for pharmacogenomic testing for patients with psychiatric conditions, including depression, general anxiety disorder, bipolar disorder, and other relevant diagnoses; Insights, which licenses libraries of linked, de-identified clinical, molecular, and imaging data; Organoids, a tumor derived biological modeling. Further, the company offers Trials for clinical trial matching services; Next, an AI platform; Algos, an algorithm-based diagnostics application. It has Strategic Collaborations with AstraZeneca AB, Pathos AI, Inc., GlaxoSmithKline, Merck, and Recursion Pharmaceuticals, Inc. Additionally, it also has a strategic collaboration with Blood Cancer United to develop registry for pediatric acute myeloid leukemia. The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc. in January 2023. Tempus AI, Inc. was incorporated in 2015 and is headquartered in Chicago, Illinois.

Visit website →